GRANITE: Airsupra Effectiveness in the Real World

Part of paid clinical trials in Wilmington, Delaware.

Sponsor
AstraZeneca
Study ID
NCT07141277
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • None (Observational study) — OTHER
    Not applicable since it's an observational study.

Study Details

The GRANITE study aims to evaluate the effectiveness of Airsupra versus albuterol in reducing asthma exacerbation risk in a real-world US population.

Key Dates

Start date
Jul 9, 2025
Status verified
Apr 2026
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
4,000 participants (estimated)

Arms

  • Arm: Airsupra cohort
    Eligible adults aged ≥18 years with asthma and at least one prescription for Airsupra
  • Arm: Albuterol cohort
    Eligible adults aged ≥18 years with asthma and at least one prescription for albuterol

Primary Outcome Measure

Baseline demographics and clinical characteristics of patients receiving Airsupra and albuterol [ Time Frame: Baseline period is 12 months prior to the index date ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
AstraZenecaWilmingtonDelaware19803-

Find similar trials in Wilmington, DE

By condition
Asthma
By specialty
PulmonologyLung disease
By research site
AstraZeneca· Wilmington, DE

Related Studies